ClinicalTrials.gg
RecruitingNCT04877093Updated Mar 31, 2026

Repurposing Low-Dose Clonidine for PTSD in Veterans

A Phase 3 interventional study of Clonidine Pill and Placebo in PTSD, Posttraumatic Stress Disorder and Sleep, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Wake Forest University Health Sciences · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Planned enrollment
1,067th of 1,491
32 · median 65
Started
2023
with 96 others
Phase 3
64 of 1,664
8 open now
Primary completion
2027-03
later than 136 of 402 live
Registered
1,098th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,067th largest by planned enrollment of the 1,491 interventional ones that give a count, is one of 97 that started in 2023, is one of 64 in phase 3, reaches primary completion later than 136 of the 402 other live ones, and was the 1,098th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.

Read the detailed description

Military veterans with Posttraumatic Stress Disorder (PTSD) suffer emotionally, physically, and socially. They have higher rates of suicide,1 issues with anger/aggression,2 substance use disorder,3 or other life difficulties (e.g., mental health disorders, marriage instability, unemployment).4 However, current first-line treatments are only effective for around half of patients receiving treatment.5,6 This is problematic given that PTSD is relatively common with a lifetime prevalence in US veterans of 10 - 31%3,7 meaning that many military veterans and their families are suffering for lack of effective treatments.

PTSD symptoms can be categorized into four clusters: re-experiencing, avoidance, cognitive or mood disturbances, and hyperarousal/reactivity.8 Symptoms may occur during the day or at night, thus disrupting sleep. Many symptoms are thought to be mediated through noradrenergic pathways. Specifically, noradrenergic overactivity may directly or indirectly affect irritability/aggression, hypervigilance, ability to concentrate, startle reactions, and sleep or other nighttime symptoms.9 These nighttime disruptions are especially problematic given that lack of sleep can exacerbate other PTSD symptoms directly or through associations with increased depression, heightened anxiety, and unstable mood/affect.10-12 Selective serotonin reuptake inhibitors (SSRI) are a first-line pharmacotherapy for PTSD, yet SSRIs do not target noradrenergic pathways, have reduced efficacy in veterans,13 and only weakly impact nighttime symptoms.11,14,15

To directly address hyperarousal and sleep, previous studies have tested medications targeting the noradrenergic pathway or sleep interventions, resulting in promising outcomes for a subpopulation of veterans with PTSD.16-27 Studies on prazosin, an antagonist of post-synaptic α1 noradrenergic receptors, have shown promise for veterans with PTSD.16,18 Clonidine is similar to prazosin and is proposed to have similar effects on PTSD; however, whereas prazosin and blocks the effects of norepinephrine, clonidine decreases norepinephrine release 28 and could therefore have greater effects on hyperarousal. Retrospective, open-label studies have suggested that clonidine use is associated with improvement in PTSD.16,17 However, no prospective studies have been published testing the effects of clonidine on PTSD, either in veterans or any other population.

Hypothesis: Veterans prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.

03

Conditions studied

  • PTSD
  • Posttraumatic Stress Disorder
  • Sleep

Keywords

  • PTSD
  • veterans
  • military
  • sleep
  • adrenergic receptor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old
  • US military veteran
  • Currently has PTSD diagnosis as determined by clinical diagnosing or by the PI
  • Screening score on PCL5 minimum of 40 (per data from previous studies36-38, a PCL5 score of 40 is roughly equivalent to a CAPS score of 30)
  • Scores ≥10 on PCL5 items 1-5 (intrusion) or scores ≥10 on PCL5 items 15-20
  • From PCL5 questionnaire, must score the following minimum in each of the following categories:

    • 1x score of 2 on Questions 1-5
    • 1x score of 2 on Questions 6-7
    • 2x score of 2 on Questions 8-14
    • 2x score of 2 on Questions 15-20
  • Has score ≥3 on CAPS nightmare items B2 and E6
  • Speaks and understands English
  • Willing to come into the clinic as programmed

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • At Moderate or High risk of suicide based on "past month" column of the Columbia-Suicide Severity Rating Scale (CSSR-S) screen version - recent.
  • Has acute or unstable mental illness or any cognitive issues which the PI determines would interfere with engagement in the study (e.g., active schizophrenia, uncontrolled bipolar, history of neurocognitive impairment, history of moderate-severe traumatic brain injury)
  • Currently receiving exposure therapy
  • Recently enrolled (\<1 month) in other behavioral health therapies (exclusions made at the PI's discretion depending on therapy type and length since admission)
  • Urgent hypertension (BP above 160/100) or symptomatic of hypertension (having a hypertensive emergency)
  • Blood pressure under 100/60 or symptoms of low blood pressure (light headedness, dizziness, heart palpitations, or other symptoms as determined by clinician).
  • Any to taking clonidine such as:

    • Known to clonidine
    • History of 2nd or 3rd degree atrioventricular block
    • History of sinus bradycardia
    • History of pheochromocytoma
    • History of Raynaud's phenomenon
    • Stage 5 Kidney disease
    • Recent myocardial infarction (\<6 months)
    • History of cerebrovascular disease or recent stoke (\<6 months)
  • Have used any of the following drugs in the past 30 days, unprescribed or not used as prescribed:

    • Heroin
    • Other opiates/analgesics
    • Barbiturates
    • Other sedatives/, hypnotics, or tranquilizers
    • Cocaine
    • Amphetamines
    • Cannabis
    • Hallucinogens
    • Inhalants
  • Currently have any of the following diagnoses:

    • Opioid use disorder
    • Cocaine use disorder
    • Alcohol use disorder
    • Cannabis use disorder
    • Sleep apnea diagnosis with verbal indication of non-adherence to treatment
  • Were prescribed clonidine within the last 6 months

    • Any α2 agonist

      • Catapres/Kapvay (clonidine)
      • Aldomet (Methyldopa)
      • Zanaflex (Tizanidine)
      • Intuniv (Guanfacine)
      • Lucemyra (Lofexidine)
    • Any α1-adrenergic antagonist

      • Prazosin
      • Terazosin
      • Doxazosin
      • Silodosin
      • Alfuzosin
      • Tamsulosin
    • Any opiate (e.g., buprenorphine, hydrocodone, oxycodone)
    • Any antipsychotic medication

      • Haldol (haloperidol)
      • Loxitane (loxapine)
      • Mellaril (thioridazine)
      • Moban (molindone)
      • Navane (thiothixene)
      • Prolixin (fluphenazine)
      • Serentil (mesoridazine)
      • Stelazine (trifluoperazine)
      • Trilafon (perphenazine)
      • Thorazine (chlorpromazine)
      • Abilify (aripiprazole)
      • Clozaril (clozapine)
      • Geodon (ziprasidone)
      • Risperdal (risperidone)
      • Seroquel (quetiapine)
      • Zyprexa (olanzapine)
    • Benzodiazepines
    • Cyproheptadine
  • Based on PI or study team assessment is cognitively unable to engage in the study
  • Has a legal guardian
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Clonidine Phase

    Participants will receive clonidine titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.

    Drug: Clonidine Pill

  • Placebo comparator
    Placebo Phase

    Participants will receive placebo titrations across 6 weeks. Note that this is a crossover design, so patients will move across phases.

    Other: Placebo

Interventions

  • DrugClonidineStudies of ClonidineClonidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.

  • OtherPlacebo

    Blinded placebo capsules will be provided to participants.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) at 6 weeks into phase

    Scored 0-21, where higher scores indicate worse sleep quality.

    Time frame: Week 6 of Current Phase

  2. Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) questions B2 and E6 at 6 weeks into phase

    Measures PTSD symptoms on sleep, with each question scored 1-4, where higher scores indicate more severe symptoms.

    Time frame: Week 6 of Current Phase

  3. Change from Baseline in PTSD Checklist-Military Version (PCL-5) at 6 weeks into phase

    Includes 20 items with a severity score range 0-80. Includes the ability to treat each item rated as 2 = "Moderately" or higher as a symptom endorsed, which allows following the DSM-5 diagnostic rule which requires at least: 1 Criterion B item (questions 1-5), 1 Criterion C item (questions 6-7), 2 Criterion D items (questions 8-14), 2 Criterion E items (questions 15-20). In general, use of a cutoff score tends to produce more reliable results than the DSM-5 diagnostic rule.

    Time frame: Week 6 of Current Phase

Secondary outcomes

  1. Change from Baseline in Patient Health Questionnaire (PHQ9) at 6 weeks into phase

    Scored 0-27, where higher scores indicate greater depression

    Time frame: Week 6 of Current Phase

  2. Change from Baseline in Sleep Diary at 6 weeks into phase

    Qualitative differences in the sleep diary responses

    Time frame: Week 6 of Current Phase

  3. Change from Baseline in quality of life scale (Q-LES-Q-SF) at 6 weeks into phase

    Scored 16-80, where higher scores indicate greater quality of life

    Time frame: Week 6 of Current Phase

07

Study locations

1 of 1 sites recruiting
  • Aurora Psychiatric Hospital
    Wauwatosa, Wisconsin 53213, United States
    Recruiting
    • Michael Fendrich, PhD · Contactmichael.fendrich@aah.org
    • Gregory A Burek, MD, MS · Principal investigator
    • Michael Fendrich, PhD · Sub investigator
08

References and documents

Publications

  • Kang HK, Bullman TA. Risk of suicide among US veterans after returning from the Iraq or Afghanistan war zones. JAMA. 2008 Aug 13;300(6):652-3. doi: 10.1001/jama.300.6.652. No abstract available. PubMed 18698062 ↗
  • Buchholz KR, Bohnert KM, Sripada RK, Rauch SA, Epstein-Ngo QM, Chermack ST. Associations between PTSD and intimate partner and non-partner aggression among substance using veterans in specialty mental health. Addict Behav. 2017 Jan;64:194-199. doi: 10.1016/j.addbeh.2016.08.039. Epub 2016 Aug 31. PubMed 27636157 ↗
  • Norman SB, Haller M, Hamblen JL, Southwick SM, Pietrzak RH. The burden of co-occurring alcohol use disorder and PTSD in U.S. Military veterans: Comorbidities, functioning, and suicidality. Psychol Addict Behav. 2018 Mar;32(2):224-229. doi: 10.1037/adb0000348. PubMed 29553778 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Mar 2027, 45 months after the start.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
May 7, 2021
StartActual
Jun 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04877093
Responsible party
Sponsor
First posted
May 7, 2021
Start date
Jun 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Kevin Petranu
Contact
kevin.petranu@aah.org
414-219-2000
Gregory Burek, MD, MS
principal investigator · Wake Forest University Health Sciences
Michael Fendrich, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clonidine

Start the discussion